LOGIN
ID
PW
MemberShip
2025-07-19 07:53
All News
Policy
Company
Product
Opinion
InterView
°Ë»ö
Dailypharm Live Search
Close
Opinion
[Reporter's View] Bio policy should remain consistent
by
Kim, Jin-Gu
Jul 17, 2025 06:13am
In November 2024, the Yoon Suk Yeol government officially announced the launch of the National Bio Committee. The government aimed to operate a 'presidential' governance body in a preparatory response to the global bioeconomy era. Considering that the previously established 'Bio-health Innovative Committee' was chaired by the Prime Minister,
Opinion
[Reporter's View] Gov¡¯t cooperation leads to a price cut?
by
Eo, Yun-Ho
Jul 16, 2025 06:10am
There are times when cooperation ends up causing losses. In an ironic twist, pharmaceutical companies that participated in the government's infertility support program have now found their products caught in the net of the Price-Volume Agreement (PVA) system, leaving them little choice but to face rapid drug price cuts. The government's i
Opinion
[Reporter¡¯s View]Biotech¡¯s responsible approach to failure
by
Cha, Jihyun
Jul 15, 2025 06:06am
Cases of terminated licensing deals and halted clinical trials are on the rise in Korea's biotech sector. Recently, IntoCell announced that the licensing agreement for its ADC (antibody-drug conjugate) platform with ABL Bio had been canceled due to patent overlap issues. Prior to that, Orum Therapeutics voluntarily decided to halt clinical d
Opinion
[Reporter's View] US tariffs¡¦variable that must be faced
by
Whang, byung-woo
Jul 11, 2025 06:12am
Tension is growing in the domestic pharmaceutical and biotech industry as President Donald Trump recently announced the potential imposition of tariffs on imported pharmaceuticals. If the tariff hike is imposed, it is expected to directly impact not only the procurement costs of raw materials and sub-materials for Korean companies but als
Opinion
[Reporter¡¯s View] Time to verify K-radiopharmaceuticals
by
Son, Hyung Min
Jul 10, 2025 06:09am
Radiopharmaceuticals are special preparations that combine drugs with radioactive isotopes for diagnostic or therapeutic use. In particular, radioligand therapy (RLT), which delivers radiation directly to tumor cells, is known for its high precision, being referred to as "moving radiation surgery." As beta particle-based radioligand thera
Opinion
[Reporter's View] The revision of the Commercial Act
by
Kim, Jin-Gu
Jul 9, 2025 06:08am
The bill on revising the Commercial Act has passed the National Assembly. The bill expands the fiduciary duty of directors to include not only the ¡°company¡± but also ¡°shareholders,¡± mandates the introduction of electronic shareholder meetings for listed companies with assets of KRW 2 trillion or more, and changes the title of ¡°outside d
Opinion
[Reporter¡¯s View] NHI finances and reimb expansions
by
Lee, Jeong-Hwan
Jul 4, 2025 06:06am
Striking a balance between improving the financial sustainability of the national health insurance system and enhancing patient access to drugs for rare and intractable diseases is a national issue. The two issues that repeatedly come into conflict have long occupied the attention of all political parties in their search for solutions, ye
Opinion
[Reporter¡¯s View] Doctors agree Korea¡¯s reimb is too slow
by
Eo, Yun-Ho
Jul 2, 2025 06:09am
Even prescribing physicians believe that the pace of new drug reimbursement listing in Korea is too slow. This is an issue not only for doctors or patients, but obviously for pharmaceutical companies as well. Recently, the Korean Research-based Pharmaceutical Industry Association (KRPIA) released the results of a survey of 100 medical pro
Opinion
[Reporter's View] Divisional restructuring needed
by
Lee, Hye-Kyung
Jun 30, 2025 06:06am
During his candidacy, President Lee Jae-myung pledged to designate the biotech industry as a cutting-edge sector and build it as the future growth engine, aiming to position South Korea as one of the world's five strongest biotech countries. Based on an analysis that the previous government was short on investment in the pharmaceutical and bi
Opinion
[Reporter's View] For local gov't seeking biotech diplomacy
by
Whang, byung-woo
Jun 30, 2025 06:05am
'BIO USA,' held in Boston, U.S., is the world's largest biotech industry conference. Notably, this year's conference was attended by officials from Korea's local government. The attending officials aimed to promote local biotech clusters and seek potential investment partners. Through this event, they intended to establish a gamer-changer
1
2
3
4
5
6
7
8
9
10
>